Calidi Biotherapeutics, Inc.
CLDI
$0.415
-$0.016-3.71%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -62.28% | -22.59% | 7.29% | 43.59% | -11.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.00% | -27.63% | -11.70% | 24.71% | 10.49% |
| Operating Income | 59.00% | 27.63% | 11.70% | -24.71% | -10.49% |
| Income Before Tax | 49.65% | -151.86% | 53.92% | -11.81% | -6.10% |
| Income Tax Expenses | 200.00% | -109.09% | 100.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | 49.59% | -150.44% | 53.87% | -11.81% | -6.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.21% | -149.70% | 53.87% | -11.81% | -6.10% |
| EBIT | 59.00% | 27.63% | 11.70% | -24.71% | -10.49% |
| EBITDA | 59.59% | 28.17% | 11.71% | -24.98% | -10.59% |
| EPS Basic | 88.39% | 54.33% | 90.20% | 72.78% | 74.48% |
| Normalized Basic EPS | 88.49% | 40.15% | 92.41% | 72.78% | 83.44% |
| EPS Diluted | 88.39% | 54.33% | 90.20% | 72.78% | 74.48% |
| Normalized Diluted EPS | 88.49% | 40.15% | 92.41% | 72.78% | 83.44% |
| Average Basic Shares Outstanding | 328.98% | 446.75% | 506.83% | 310.77% | 315.68% |
| Average Diluted Shares Outstanding | 328.98% | 446.75% | 506.83% | 310.77% | 315.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |